Merck and Google Cloud partner on USD 1b agentic AI deployment across R&D and operations

Merck (NYSE: MRK) and Google Cloud announced a multi-year technology collaboration valued at up to USD 1 billion to deploy an agentic AI platform across Merck’s R&D, manufacturing, commercial, and corporate functions. The agreement centers on Google Cloud’s Gemini Enterprise models, with Google Cloud engineers embedded alongside Merck teams to co-develop and deploy solutions across the company’s global workforce of 75,000 employees and the entire pharma value-chain.

Under the terms disclosed, Merck will deploy Gemini Enterprise across end-to-end R&D workflows, apply predictive analytics and intelligent automation to manufacturing operations, and use AI-driven personalization tools in commercial and patient engagement functions. Corporate productivity applications are also within scope. The agreement does not specify an upfront payment, milestone structure, or royalty terms, which are structurally inapplicable to a technology services arrangement of this type. The USD 1 billion figure represents a ceiling on the multi-year investment, with no timeline or contingency breakdown disclosed. Geographic scope is implicitly global given Merck’s operational footprint, though no territorial provisions were formally defined in the announcement.

The development model places Google Cloud engineers directly within Merck’s teams, indicating a co-deployment structure rather than a conventional vendor-client relationship. Merck retains ownership of its scientific data assets and domain expertise, which serve as the primary inputs into the platform. Google Cloud contributes the AI infrastructure, Gemini models, and technical personnel.

Merck enters the agreement at a point of strategic pressure, with its PD-1 inhibitor facing patent expiry around 2028, creating urgency around pipeline replenishment and operational cost reduction. An enterprise-wide AI deployment that spans discovery, manufacturing, and commercial functions addresses both dimensions simultaneously, though the financial returns from such infrastructure investments are measured in operational efficiency and development speed rather than asset-specific milestones.

Merck’s agreement with Google Cloud builds on earlier, more modular cloud partnerships in the sector, including Sanofi and Roche’s collaborations with Google Cloud focused on data platforms and AI-enabled R&D, though these stopped short of full enterprise-wide deployment.

Similarly, Pfizer has worked with Amazon Web Services on cloud-based analytics and drug development workflows, but without the centralized, agentic AI layer and embedded engineering model outlined in the Merck deal.